How a physician rollup became the first test of the “Extend-and-Exchange” LME
How the Pharmaceutical Enron restructuring solved the near-term debt wall, but the endgame is still uncertain
How insurance fraud dragged an unconventional software rollup into Chapter 11
A litigation-riddled company, challenges in healthcare regulations, and the fascinating dynamic of insider structures within a Chapter 11 bankruptcy.
Overview of Rite Aid, Signs of Distress, Alternatives to Chapter 11, 2.0 Plan, 363 Asset Sale of Elixir, and many more topics
Key Players, The Unit Economics of a Pharmacy, Comparison of Business Models, Factors Behind Financial Distress, Solutions to Address Liquidity Crunch
In the article below, we will cover this industry: its origins, major players, market performance, key criticisms, and much more. This is a fascinating sector that most of us rarely interact with.
If you bought Danaher stock in 1984, you would have returned 192,208%
Diving deep into YesCare and its unique Texas Two Step restructuring
